Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: J05AE02

Crixivan(indinavir sulfate ethanolate)

HIV Infections

Marketing Authorisation Holder: Merck Sharp & Dohme B.V.

EMA Authorisation: 04/10/1996

INN: indinavir

Indication

Crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Crixivan — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.